…, YG Lin, LS Mangala, TJ Kim, RL Coleman… - Nature medicine, 2006 - nature.com
Stress can alter immunological, neurochemical and endocrinological functions, but its role in
cancer progression is not well understood. Here, we show that chronic behavioral stress
results in higher levels of tissue catecholamines, greater tumor burden and more invasive …

CV Pecot, GA Calin, RL Coleman… - Nature Reviews …, 2011 - nature.com
Inherent difficulties with blocking many desirable targets using conventional approaches
have prompted many to consider using RNA interference (RNAi) as a therapeutic approach.
Although exploitation of RNAi has immense potential as a cancer therapeutic, many …

[HTML][HTML]

…, G Lopez-Berestein, RL Coleman… - … England Journal of …, 2008 - Mass Medical Soc
Background We studied Dicer and Drosha, components of the RNA-interference machinery,
in ovarian cancer. Methods We measured messenger RNA (mRNA) levels of Dicer and
Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a …

BT Hennessy, RL Coleman, M Markman - The lancet, 2009 - Elsevier
The standard initial management of epithelial ovarian cancer consists of surgical staging,
operative tumour debulking including total abdominal hysterectomy and bilateral salpingo-
oophorectomy, and administration of six cycles of intravenous chemotherapy with …

WP Sweezer, J Jimison, RL Coleman - US Patent 5,478,309, 1995 - Google Patents
A catheter system and method for achieving total cardiopulmonary bypass during heart
surgery. A venous perfusion catheter is inserted peripherally into a preselected vein where it
is advanced and positioned at the atrio-caval junction. The venous perfusion catheter has …

JJ Workman, CR Lambert, RL Coleman - US Patent 8,509,867, 2013 - Google Patents
This invention provides devices, compositions and methods for determining the
concentration of one or more metabolites or analytes in a biological sample, including cells,
tissues, organs, organisms, and biological fluids. In particular, this invention provides …

…, H Giordano, J Sun, GE Konecny, RL Coleman… - The lancet oncology, 2017 - Elsevier
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2
(BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous …

[PDF][PDF]

C Levenback, RL Coleman, TW Burke, WM Lin… - Journal of Clinical …, 2002 - Citeseer
Purpose: The purpose of this study was to determine the feasibility of sentinel node
identification in patients with invasive cervix cancer undergoing radical hysterectomy and
pelvic lymphadenectomy using preoperative and intraoperative lymphatic mapping. Patients …

…, M Miller, BP Kearney, RL Coleman… - Antimicrobial agents …, 2001 - Am Soc Microbiol
Tenofovir DF is an antiviral nucleotide with activity against human immunodeficiency virus
type 1 (HIV-1). The pharmacokinetics, safety, and activity of oral tenofovir DF in HIV-1-
infected adults were evaluated in a randomized, double-blind, placebo-controlled …

[HTML][HTML]

…, EO Guven, YH Chen, LY Li, MC Hsu, RL Coleman… - Cancer cell, 2010 - Elsevier
Although VEGF-targeted therapies are showing promise, new angiogenesis targets are
needed to make additional gains. Here, we show that increased Zeste homolog 2 (EZH2)
expression in either tumor cells or in tumor vasculature is predictive of poor clinical outcome …